The future challenges in Parkinson's disease

Journal of Neurology

Volumn 251, Issue 3, 2004, Pages 361-365

  Barker, Roger A ^a   Foltynie, Thomas ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; DNA; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR;

BASAL GANGLION; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; EMBRYO CELL; GENE EXPRESSION; GENOME; HUMAN; NEUROLOGIC DISEASE; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION;

ANIMALS; ANTIPARKINSON AGENTS; HUMANS; PARKINSON DISEASE; STEM CELL TRANSPLANTATION;

EID: 1642299753     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-0320-8     Document Type: Review

References (28)

1. Arnsten AF (1997) Catecholamine regulation of the prefrontal cortex. J Psychopharmacol 11:151-162
2. Arnsten AF, Cai JX, Murphy BL, Goldman-Rakic PS (1994) Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 116:143-151
3. Barker RA (2002) Repairing the brain in Parkinson's disease: where next? Mov Disord 17:233-241
4. Barker RA, Jain M, Armstrong RJE, Caldwell MA (2003) Stem cells and neurological disease. J Neurol Neurosurg Psychiatry 74:553-557
5. Bjorklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, Isacson O (2002) Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 99:2344-2349
6. Burn DJ (2002) Depression in Parkinson's disease. Eur J Neurol 9(suppl 3):44-54
7. Burn DJ, Mark MH, Playford ED, Maraganore DM, Zimmerman-TR J, Duvoisin RC, Harding AE, Marsden CD, Brooks DJ (1992) Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology 42:1894-1900
8. Cools R, Barker RA, Sahakian BJ, Robbins TW (2001) Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 11:1136-1143
9. Foltynie T, Brayne C, Barker RA (2002) The heterogeneity of idiopathic Parkinson's disease. J Neurol 249:138-145
10. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S (2001) Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-719
11. Gage FH (2002) Neurogenesis in the adult brain. J Neurosci 22:612-613
12. Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, Sainz J, Frigge ML, Kong A, Gulcher JR, Stefansson K, Sveinbjornsdottir S (2002) A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 52:549-555
13. Hotton GR, Gill SS, Patel NK, Heywood P, Svensen CN, Brooks DJ (2002) Chronic intraputaminal infusion of glial derived neurotrophic factor (GDNF) in the treatment of advanced Parkinson's disease: An 18F-dopa PET study. Mov Disord 17:S189
14. Hurelbrink CB, Barker RA (2001) Prospects for the treatment of Parkinson's disease using neurotrophic factors. Expert Opin Pharmacother 2:1531-1543
15. Kaasinen V, Nurmi E, Bruck A, Eskola O, Bergman J, Solin O, Rinne JO (2001) Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 124:1125-1130
16. Kim JH, Auerbach JM, Rodriguez-Gomez JA, Velasco I, Gavin D, Lumelsky N, Lee SH, Nguyen J, Sanchez-Pernaute R, Bankiewicz K, McKay R (2002) Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418:50-56
17. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Cochran EJ, Mufson EJ, Penn R, Goetz CG, Comella CD (1999) Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46:419-424
18. Levesque MF, Neuman T (2002) Autologous transplantation of differentiated dopaminergic neurons for Parkinson's disease: long-term post-operative, clinical and functional metabolic results. Exp Neurol 175:2
19. Lidow MS, Koh PO, Arnsten AF (2003) D1 dopamine receptors in the mouse prefrontal cortex: Immunocytochemical and cognitive neuropharmacological analyses. Synapse 47:101-108
20. Murphy BL, Arnsten AF, Jentsch JD, Roth RH (1996) Dopamine and spatial working memory in rats and monkeys: pharmacological reversal of stress-induced impairment. J Neurosci 16:7768-7775
21. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Jr, Lozano AM, Penn RD, Simpson RK, Jr, Stacy M, Wooten GF (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60:69-73
22. Olanow C (2002) Transplantation for Parkinson's disease: Pros, cons, and where do we go from here? Mov Disord 17:S15
23. Owen AM, James M, Leigh PN, Summers BA, Marsden CD, Quinn NP, Lange KW, Robbins TW (1992) Frontostriatal cognitive deficits at different stages of Parkinson's disease. Brain 115:1727-1751
24. Riley DE, Chelimsky TC (2003) Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson's disease. J Neurol Neurosurg Psychiatry 74:56-60
25. Wakabayashi K, Takahashi H (1997) Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 38(suppl 2):2-7
26. Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, Rothwell JC, Brown R, Gustavii B, Hagell P, Jahanshahi M, Sawle G, Bjorklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O (1997) Short-and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42:95-107
27. Whone AL, Moore RY, Piccini PP, Brooks DJ (2003) Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol 53:206-213
28. Yoshita M (2000) Loss of 123I-metaiodobenzylguanidine uptake by the heart in Parkinson's disease. J Nucl Med 41:1442